Trastuzumab biosimilars saw significant market uptake in Japan after reimbursement incentives were implemented, but ...

Biocon Biologics Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved JOBEVNE™ (bevacizumab-nwgd), a ...

In a live virtual event, Thomas C. Krivak, MD, reviewed the key studies of PARP inhibitor and bevacizumab maintenance in ...

The Food and Drug Administration (FDA) has accepted for review a resubmission of the Biologics License Application (BLA) for bevacizumab-vikg (ONS-5010) for the treatment of wet age-related macular ...

Bristol-Myers Squibb has claimed its second FDA approval in the space of a few days for its immuno-oncology combination of ...

The US Food and Drug Administration (FDA) has approved bevacizumab-nwgd (Jobevne, Biocon Biologics Ltd), a biosimilar to bevacizumab (Avastin, Genentech), for intravenous use across multiple cancer ...

Biocon’s share price rose 5.5% after USFDA approved JOBEVNE, a biosimilar cancer drug. This marks the company’s seventh USFDA ...

Biocon Biologics has gained approval from the US Food and Drug Administration (FDA) for the intravenous use of Jobevne ...

The U.S. Food and Drug Administration has approved Jobevne (bevacizumab-nwgd), a biosimilar to Avastin (bevacizumab) for ...

Biocon Biologics, a subsidiary of India-based Biocon Ltd, said on Thursday that U.S. FDA has approved Jobevne, a biosimilar ...

The FDA has accepted the resubmission of the biologics license application (BLA) for ONS-5010 (bevacizumab-vikg) for the ...

The FDA has approved bevacizumab-nwgd, a biosimilar to bevacizumab, for intravenous use across multiple cancer types.